thymosin alpha-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
In November 1979, Gunther von Hagens applied for a German patent, proposing the idea of preserving animal and vegetable tissues permanently by synthetic resin impregnation. Since then, von Hagens has applied for further US patents regarding work on preserving biological tissues with polymers. With the success of his patents, von Hagens went on to form the Institute for Plastination in Heidelberg, Germany in 1993. The Institute for Plastination, along with von Hagens, made their first showing of plastinated bodies in Japan in 1995, which drew more than three million visitors. The institute maintains three international centres of plastination, in Germany (Heidelberg-Rohrbach), Kyrgyzstan, and China.
=== Medical equipment === The medical equipment approach involves combining a continuous glucose monitor and an implanted insulin pump that can function together with a computer-controlled algorithm to replace the normal function of the pancreas. The development of continuous glucose monitors has led to the progress in artificial pancreas technology using this integrated system.
=== Discontinued === AS-601811 – oral – male pattern baldness – 5α-reductase inhibitor ATI-501 (A-201; ATI-50001) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor Brepocitinib (PF-06700841) – oral – alopecia, alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor Cioteronel (CPC-10997; Cyoctol, X-Andron) – topical – alopecia – androgen receptor antagonist Diazoxide – topical – alopecia – potassium channel opener Denileukin diftitox (Lymphirtm, Ontak, Remitoro; LY-335348; DAB389 interleukin-2) – unknown – alopecia – protein synthesis inhibitor Epristeride (Aipuliete; ONO-9302, SKF-105657) – oral – alopecia – 5α-reductase inhibitor Etrasimod (Verespiti, Velspity; APD-334, PF-07915503) – oral – alopecia areata – sphingosine 1 phosphate receptor modulator Farudodstat (ASLAN-003, LAS-186323) – oral – alopecia areata – dihydroorotate dehydrogenase inhibitor HST-001 (HSC-660) – intradermal – alopecia – intercellular signalling peptide and protein replacement Ifidancitinib (A-301, ATI-50002, ATI-502) – topical – alopecia, alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor MK-434 (MK-0434) – oral – alopecia – 5α-reductase inhibitor Naminidil (BMS-234303) – topical – alopecia – potassium channel opener NEOSH–101 – topical – alopecia – undefined mechanism of action P-1075 – unknown – alopecia – potassium channel opener Piliel – topical – alopecia – undefined mechanism of action Research programme: androgen receptor antagonists - Endoceutics (EM-4350, EM-6537) – unknown – male pattern baldness – androgen receptor antagonists Research programme: oligonucleotide therapeutics for alopecia - OliPass – unknown – alopecia – androgen receptor antagonists RU-58841 (PSK-3841, HMR-3841) – topical – alopecia – androgen receptor antagonist Secukinumab (Cosentyx) – injection – alopecia areata – IL17A protein inhibitor Setipiprant (ACT-129968, KYTH-105) – oral – alopecia – prostaglandin D2 receptor antagonist Timbetasin (thymosin β4) – unknown – alopecia – various mechanisms of action Tralokinumab (Adbry, Adtralza; CAT-354, LP-0162) – subcutaneous injection – alopecia areata – interleukin-13 inhibitor TU-2100 – topical – hair disorders – undefined mechanism of action Viprostol (CL-115347) – topical – alopecia – synthetic prostaglandin E2 analogue
Sources: en.wikipedia.org
Prokaryotes are not as structurally complex as eukaryotes, and were once thought to have little internal organization, and lack cellular compartments and internal membranes; but slowly, details are emerging about prokaryotic internal structures that overturn these assumptions. An early false turn was the idea developed in the 1970s that bacteria might contain cell membrane folds termed mesosomes, but these were later shown to be artifacts produced by the chemicals used to prepare the cells for electron microscopy. However, there is increasing evidence of compartmentalization in at least some prokaryotes. Research has revealed that at least some bacteria have microcompartments, such as carboxysomes. These subcellular compartments are 100–200 nm in diameter and are enclosed by a shell of proteins. Even more striking is the description of membrane-bound magnetosomes in magnetotactic bacteria, reported in 2006. The bacterial phylum Planctomycetota has revealed a number of compartmentalization features. The Planctomycetota cell plan includes intracytoplasmic membranes that separates the cytoplasm into paryphoplasm (an outer ribosome-free space) and pirellulosome (or riboplasm, an inner ribosome-containing space). Membrane-bounded anammoxosomes have been discovered in five Planctomycetota "anammox" genera, which perform anaerobic ammonium oxidation. In the Planctomycetota species Gemmata obscuriglobus, a nucleus-like structure surrounded by lipid membranes has been reported. Compartmentalization is a feature of prokaryotic photosynthetic structures.
Psilocybin's psychedelic effects can be blocked by serotonin 5-HT2A receptor antagonists like ketanserin and risperidone in humans. Activation of serotonin 5-HT2A receptors in layer V of the medial prefrontal cortex (mPFC) and consequent glutamate release in this area has been especially implicated in the hallucinogenic effects of psilocybin and other serotonergic psychedelics. In addition, region-dependent alterations in brain glutamate levels may be related to the experience of ego dissolution. The cryo-EM structures of the serotonin 5-HT2A receptor with psilocin, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues. Although serotonin 5-HT2A receptor agonism mediates the hallucinogenic effects of psilocybin and psilocin, activation of other serotonin receptors also appears to contribute to these compounds' psychoactive and behavioral effects. Serotonin 5-HT1A receptor activation seems to inhibit the hallucinogenic effects of psilocybin and other psychedelics. Some of psilocybin's non-hallucinogenic behavioral effects in animals can be reversed by antagonists of the serotonin 5-HT1A, 5-HT2B, and 5-HT2C receptors. Psilocybin produces profoundly decreased locomotor and investigatory behavior in rodents, and this appears to be dependent on serotonin 5-HT1A receptor activation but not on activation of the serotonin 5-HT2A or 5-HT2C receptors.
For example, for a sucrose ester mixture containing 80% of sucrose monoester, HLB = 16. This equation has been applied regardless the length of the fatty chain. A correspondence table can be written for different grades of sucrose esters according to this equation. The values calculated correspond quite closely with the data given by the suppliers (the data have been harvested from the respective suppliers' websites in March 2020).
Sources: en.wikipedia.org
Moreover, Esimone's research team was the first to demonstrate the occurrence of the FOX-1 gene, responsible for expressing the AmpC enzyme in gram-negative bacteria in Nigeria. This enzyme significantly enhances the ability of organisms to resist cephamycin antibiotics.
Nuclear warfare, also known as atomic warfare, is a military conflict or prepared political strategy that deploys nuclear weaponry. Nuclear weapons are weapons of mass destruction; in contrast to conventional warfare, nuclear warfare can produce significantly more destruction in a much shorter time and can have a long-lasting radiological result. A large nuclear exchange would kill hundreds of millions of people. It would have long-term effects, from the fallout released, and could also lead to secondary effects, such as nuclear winter, nuclear famine, and societal collapse. A global nuclear war with current national stockpiles may lead to various devastating scenarios, including human extinction. As of 2026, the first and only use of nuclear weapons in armed conflict was the United States atomic bombings of Hiroshima and Nagasaki, on August 6 and 9, 1945, in the final days of World War II. The two bombings resulted in the deaths of between 150,000 and 246,000 people. A debate continues over ethical, legal, and military aspects of the bombings, including their role in the surrender of Japan. The Cold War prompted the nuclear arms race. Nuclear weapons were later developed by the Soviet Union (1949), the United Kingdom (1952), France (1960), and China (1964). In 1974, India, and in 1998, Pakistan, with a history of conflict, developed nuclear weapons. Israel (1960s) and North Korea (2006) also developed nuclear weapons.
During the period when Germany was divided, the Lower Saxon border crossing at Helmstedt found itself on the main transport artery to West Berlin and, from 1945 to 1990 was the busiest European border crossing point. Of economic significance for the state was the Volkswagen concern, that restarted the production of civilian vehicles in 1945, initially under British management, and in 1949 transferred into the ownership of the newly founded country of West Germany and state of Lower Saxony. Overall, Lower Saxony, with its large tracts of rural countryside and few urban centres, was one of the industrially weaker regions of the federal republic for a long time. In 1960, 20% of the working population worked on the land. In the rest of the federal territory the figure was just 14%. Even in economically prosperous times the jobless totals in Lower Saxony are constantly higher than the federal average. In 1961 Georg Diederichs took office as the minister president of Lower Saxony as the successor to Hinrich Wilhelm Kopf. He was replaced in 1970 by Alfred Kubel. The arguments about the Gorleben Nuclear Waste Repository, that began during the time in office of minister president Ernst Albrecht (1976–1990), have played an important role in state and federal politics since the end of the 1970s. In 1990 Gerhard Schröder entered the office of minister-president. On 1 June 1993, the new Lower Saxon constitution entered force, replacing the "Provisional Lower Saxon Constitution" of 1951.
Creatine is an organic acid naturally occurring in the body (and in red meats) that supplies energy to muscle cells for short bursts of energy (as required in lifting weights) via creatine phosphate replenishment of ATP. Scientific studies have shown that creatine supplementation can increase the consumer's strength, energy during performance, muscle mass, and recovery times after exercise. In addition, recent studies have also shown that creatine improves brain function and reduces mental fatigue. Some studies have suggested that consumption of creatine with protein and carbohydrates can have a greater effect than creatine combined with either protein or carbohydrates alone. While generally considered safe, long-term or excessive consumption of creatine may have an adverse effect on the kidneys, liver, or heart and should be avoided if any pre-existing conditions affecting these organs exist.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.